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Abstract 
This paper provides a position statement regarding decision making under uncertainty within the 
economic evaluation of pharmaceuticals, with a particular focus upon the National Institute for Health 
and Clinical Excellence context within England and Wales. This area is of importance as funding 
agencies have a finite budget from which to purchase a selection of competing health care interventions. 
The objective function generally used is that of maximising societal health with an explicit 
acknowledgement that there will be opportunity costs associated with purchasing a particular 
intervention. Three elements of decision uncertainty are discussed within a pharmaceutical funding 
perspective: methodological uncertainty; parameter uncertainty and structural uncertainty, alongside a 
discussion around value of additional information. Methods development has focussed primarily on 
handling parameter uncertainty and a clear reference case has been developed for consistency across 
evaluations, however, uncertainties still remain. Less attention has been given to methods for handling 
structural uncertainty; the lack of adequate methods to explicitly incorporate this aspect of model 
development may result in the true uncertainty surrounding health care investment decisions being 
underestimated. Research in this area is ongoing. 
 
Key Words: Uncertain data, robust procedure, health economics, value of information, mathematical 
modelling. 
 
Background 
This manuscript was prepared for discussion at the 25th Mini-EURO Conference on 
Uncertainty and Robustness in Planning and Decision Making which had the aim of integrating 
methodologies used by different research communities. Accordingly, we have set out the methodologies 
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used within decision making in the evaluation of health technologies, (a relatively new discipline), mainly 
in terms of the National Institute for Health and Clinical Excellence (NICE) context within England and 
Wales, in order that researchers in other fields understand how health economists deal with uncertainty. 
This consists of: an introduction to health economic evaluation; NICE technology appraisals; a taxonomy 
of uncertainty used in health technology assessments; representing uncertainty around the objective 
function; alternative decision making criteria , and value of additional information. 
Introduction to health economic evaluation 
The finite budget for health care in conjunction with the number of potential treatments results in a 
position where not all treatments can be funded. Consequently there is a need to quantify the opportunity 
costs in terms of the health outcomes lost by curtailing existing services in order to fund the new 
intervention. Attempts to maximise societal health from a limited budget has led to funding bodies such 
as, being established to provide guidance in England and Wales on whether pharmaceuticals should be 
recommended for routine use on the NHS. At the present time, such recommendations carry a mandate 
for funding by the health service. The Pharmaceutical Benefits Advisory Committee, the Canadian 
Agency for Drugs and Technology in Health and the Scottish Medical Consortium, hold similar positions 
in Australia, Canada and Scotland respectively. In all jurisdictions the decision will be made in the 
presence of uncertainty. 
Due to the collective experience of the authors as a NICE appraisal committee member, and as authors of 
reports for consideration by NICE representing both academia and pharmaceutical perspectives, NICE is 
the key reference point. Additionally NICE represents an exemplar in that its decision making approach is 
largely focussed on the formal consideration of opportunity cost under conditions of uncertainty. Some of 
the key concepts will apply to other funding agencies.  
NICE technology appraisals  
NICE makes recommendations to the NHS within England and Wales on selected new and existing 
medications, treatments and procedures. It is an independent body which aims to produce guidance for 
health professionals using the best available evidence, with a focus on transparency regarding the decision 
making process. The decision for or against the use of a given health technology is made by an 
independent appraisal committee, appointed for a 3-year term consisting of members drawn from the 
NHS, patient and carer organisations, academia and pharmaceutical and medical devices industries and 
which is free from political influence. There are two types of technology appraisal: the single technology 
appraisal (STA) and the multiple technology appraisal (MTA). An STA is specifically designed for the 
appraisal of a single health technology, with a single indication, whereby most of the relevant evidence 
lies with one manufacturer; in this instance the manufacturer submits a report and model which is 
critiqued by an independent academic group. In an MTA, where multiple interventions are being 
appraised, the academic group constructs a mathematical model; the methods and results of which are 
discussed in comparison with those produced by the manufacturers. The STA process was developed to 
produce more timely guidance, but guidance may be delayed if additional analyses are required following 
the committee meeting to resolve concerns regarding the robustness of the submitted evidence. The 
preliminary guidance is subject to public consultation which is considered before final guidance is 
developed. 
The appraisals undertaken by NICE are typically posed in the form ³VKRXOG ZH EX\ SURJUDPPH $ RU
programme B for the treatment of disease &LQSRSXODWLRQ'"´ These are substance focussed motivations 
(Morgan and Henrion 1992) in that there is a specifically formulated policy question that will be directly 
considered. The evaluation criterion is the incremental cost per Quality Adjusted Life Year (QALY) 
gained, which is a common metric intended to provide a level playing field such that decisions can be 
taken consistently across treatments and disease areas.  
 
 
The QALY combines increased life expectancy and improvements in health status by assigning to each 
period of time a utility ranging from 0 to 1, corresponding to the health-related quality of life during that 
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period. A utility score of 1 corresponds to ³SHUIHFWhealth´, whilst a utility of 0 corresponds to a health 
state judged to be equivalent to death (Weinstein and Statson, 1977). Utility scores lower than zero 
represent states of health that are judged to be worse than death. Health utilities may be elicited using a 
range of preference-based methods which, in general, seek to trade-off DQLQGLYLGXDO¶VSUHIHUHQFHVIRURne 
state of health over another under conditions of uncertainty. The QALY approach thus adjusts survival 
DFFRUGLQJWRWKHLQGLYLGXDO¶VOHYHORIKHDOWK-related quality of life. A person who survives 10 years at a 
utility of 0.8 will gain eight QALYs. The benefits of a treatment that increases survival at a utility of 0.8 
(from 10 to 20 years) or improves the quality of the 10 years (from 0.8 to 0.9) can be valued in terms of 
the QALY gain (i.e. gains of eight and one, respectively).  
 
The incremental cost per QALY ratio is compared with defined thresholds in the decision making 
process. Guidance from NICE has suggested that treatments with an incremental cost per QALY of below 
£20,000 per QALY are likely to receive funding, whilst those above £30,000 per QALY are unlikely to 
receive funding, (NICE, 2008) although a higher threshold may be used for a subset of interventions 
which meHWµHQGRIOLIH¶FULWHULD (NICE, 2009). The central underlying assumption is that the successive 
implementation of this threshold approach will move towards a health maximising solution. 
 
A taxonomy of sources of uncertainty within health technology assessments. 
 
Economic modelling involves projecting forward to estimate profiles of expected costs and health 
outcomes for each intervention under consideration over a time horizon which ideally captures all 
differences in costs and health outcomes between the intervention(s) and the comparator(s). Profiles of 
cost and health outcomes (survival, quality of life or both) are then compared incrementally and 
synthesised to produce an expected incremental cost per QALY ratio. Health economic models often 
draw together evidence concerning the natural history of a disease, epidemiology, treatment effectiveness, 
adverse events, resource use and costs. Uncertainty surrounding the use of such models, and more broadly 
around the decision problem to be addressed by the model, is pervasive; its importance is manifested in 
the possibility that the adoption decision may be incorrect. An incorrect decision would lead to inefficient 
allocation of resources and hence sub-optimal health gains for society.  
 
 
This paper outlines current approaches to handling three different but overlapping elements of decision 
uncertainty:  
1. Methodological uncertainty ± uncertainty surrounding the methods used to underpin the 
evaluation e.g. specification of the objective function, discount rates, the time horizon and the 
measurement and valuation of costs and health outcomes 
2. Parameter uncertainty ± uncertainty surrounding the true mean values of model parameters 
3. Structural uncertainty ± uncertainty surrounding the conceptual and mathematical representation 
of a decision problem within a model.  
 
This taxonomy has emerged as a common language within the field of health economics. For 
completeness, an alternative interdisciplinary taxonomy of the sources of uncertainty is discussed within a 
health economic context.   
 
 
1) Methodological uncertainty 
 
Within health technology evaluations for NICE methodology uncertainty is handled using a Reference 
Case (NICE, 2008) The Reference Case stipulates the metric of the cost per QALY and also prescribes a 
common discount rate applied to handle preferences in the timing of accrued costs and outcomes, relevant 
comparators for the model, a consistent focus on costs and outcomes incurred by the NHS and Personal 
Social Services and specific approaches to measuring and valuing the health outcomes and costs 
associated with health interventions. In addition, the Reference Case requires that uncertainty around 
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model parameters should be handled within a multivariate probabilistic sensitivity analysis (PSA). It is 
acknowledged that there will be uncertainty in the values and approaches chosen by NICE for the 
Reference Case, but that this is outside of the control of the modeller within this context and will not be 
discussed further here. 
 
 
2) Parameter uncertainty 
 
The appropriate handling of parametric uncertainty has been the focus of considerable methodological 
development in health economics for over 20 years. Uncertainty exists in key parameters that are 
incorporated into mathematical models such as the efficacy of treatment, the natural history of patients 
who do not receive the intervention, relationships between intermediate and final outcomes and the level 
of health-related quality of life associated with being in a particular health state, for example having 
sustained a hip fracture. Even where well conducted randomised controlled trials have been undertaken, 
uncertainty will still be present due to finite trial sizes and insufficient follow up to consider all impacts 
upon future costs and health outcomes. 
 
PSA uses Monte Carlo methods to simultaneously sample from all uncertain distributions associated with 
each parameter in order to produce distributions of incremental costs and health outcomes. This 
uncertainty can then be interpreted in terms of the probability that the given technology is cost-effective 
over a range of acceptable cost-effectiveness thresholds. Conducting PSA is fundamentally important 
because if the model is non-linear then the results calculated from the PSA may be markedly different to 
those calculated using the mean value (as recommended by NICE) estimate from each distribution. 
(Claxton et al., 2005) Typically crude Monte Carlo techniques have been employed to perform PSA, 
although alternative approaches using meta-modelling (Stevenson et al., 2004) and through calculating an 
efficient ratio of the number of individuals sampled to the numbeURI36$SDUDPHWHUV 2¶+DJDQHWDO
2007) have been proposed.  
 
Early health economic models assumed independence when sampling from the distributions for each 
parameter, however the use of the Cholesky decomposition, which explicitly takes into account 
correlation between variables and the dirichelet distribution which appropriately samples the proportions 
of patients that fall into mutually exclusive and exhaustive groups are now commonly used. Further 
details on these distributions are provided in Briggs et al., 2006.   
 
Three developments in addressing parameter uncertainty that are particularly pertinent within the 
discipline are explicitly discussed. These are mixed treatment comparisons or Network Meta-Analyses, 
fitting statistical curves to censored survival data and methods for dealing with patient cross-over within a 
trial. 
 
Network meta-analysis is a generalisation of standard pair-wise meta-analysis that derives estimates of 
treatment effects from a synthesis of direct and indirect evidence (Caldwell et al., 2005), (Lu and Ades, 
2006) which ensures that the output from a combination of different evidence sources are consistent. This 
contrasts with direct head-to-head evidence (for which the NICE Reference Case has a strong preference), 
which can (in an extreme) produce discrepancies where intervention A is assumed to be more efficacious 
than intervention B, intervention B is assumed to be more efficacious than intervention C yet intervention 
C is assumed more efficacious than intervention. Furthermore it has been shown that assuming direct 
evidence produces more accurate estimates of relative efficacy than the estimates estimated through a 
network meta-analysis where the two are discordant is not always correct. Madan et al., (In Press) provide 
an example where the initials estimate of efficacy obtained from a network meta-analysis was discordant 
with the direct evidence, but following subsequent trials (where the estimates from both methods were 
now in agreement) it was shown that initially the estimate from the network meta-analysis was more 
accurate. 
 
It is typical that a clinical trial is terminated before all patients have had an event. In this instance a 
substantial proportion of the observations are censored and a number of statistical distributions could be 
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used to provide a plausible fit to the data. The importance of this was shown in a NICE appraisal of 
sorafenib for hepatocellular cancer. Both the lognormal and weibull distributions produced a reasonable 
fit to the observed data and had similar Akaike Information Criterion (AIC) and Bayesian Information 
Criterion (BIC) values; however, differences in the tails of the distributions produced markedly different 
cost-effectiveness ratios (£64,754 and considerably higher (commercial-in-confidence) respectively)  
 
Within a clinical trial, it is possible that an intervention is shown to be substantially more efficacious than 
a comparator (possibly placebo) arm before the trial has completed. In this circumstance, patients within 
the comparator arm are often crossed-over and receive the intervention. Whilst ethically just, this creates 
problems in performing intention to treat analyses (where patients are classified solely on their initial 
treatment allocation) due to confounding, as the comparator would very likely do better because of the 
cross-over than would have been the case had patients continued with their initial treatment, which can 
have dramatic influences on the resulting cost-effectiveness ratio. Simple correction methods such as 
exclusion or censoring of observations are likely to lead to severe selection bias and more complex 
methods such as rank preserving structural failure time (RPSFT) models (Robins and Tsiatis, 1991) and 
inverse probability of censoring weights (IPCW) (Robins and Finkelstein, 2000) have been used in 
submissions to NICE. The RPSFT uses the randomisation assumption to estimate treatment effect such 
that counterfactual survival (a function of observed survival time, observed treatment and the treatment 
effect) would have been equal in randomised groups had no experimental treatment been given to any 
patients. The IPCW approach treats crossover patients as informatively censored, and applies time-
varying weights to uncensored survival probabilities based on the probability of patients crossing over 
given their covariate history.  The IPCW approach is reliant on the assumption of no unmeasured 
confounders, and upon the existence of a reasonable number of uncensored observations. Research is 
currently ongoing to determine which method is most applicable in health technology 
evaluations.(reference?) 
 
 
3) Structural uncertainty 
Structural uncertainty relates to whether all relevant processes are represented in the model, that is, what 
is included and excluded and how the relationships between inputs and outputs are captured. Recent 
empirical work has highlighted marked heterogeneity in the development of health economic models 
(Tappenden et al., 2009). Methods for handling structural uncertainty are relatively underdeveloped in the 
field of health economics, yet structural uncertainties can often have a greater impact upon the model 
results than parameter uncertainties. This means that the estimated uncertainty within the model outputs 
resulting from PSA is likely to be underestimated, as such estimates are reliant on the assumption that the 
model structure is optimal. The NICE Methods Guide (NICE, 2008) VWDWHV WKDW µstructural assumptions 
should be clearly documented and the evidence and rationale to support them provided. The impact of 
structural uncertainty on estimates of cost effectiveness should be explored by separate analyses of a 
UHSUHVHQWDWLYHUDQJHRISODXVLEOHVFHQDULRV¶These methods can provide an indication around the impact 
of uncertainties regarding key structural assumptions upon the model results. However, the overall model 
uncertainty cannot be captured using these methods. 
 
A µPRGHO DYHUDJLQJ¶ PHWKRG has been proposed (Bojke et al., 2009) for handling the propagation of 
structural uncertainty through the model. This involves parameterising all identified structural 
uncertainties within the model and weighting each according to their likelihood, often estimated using 
elicitation of expert judgement. These µVWUXFWXUDOXQFHUWDLQW\¶parameters would be varied within the PSA 
in the same way as other model parameters. The model results could therefore account for both parameter 
and structural uncertainties. However, the feasibility of this method for complex problems with many 
structural uncertainties has not been demonstrated. Moreover, structural uncertainties not identified within 
the model construction process, which may markedly change the results, are ignored. A µGLVFUHSDQF\¶
approach has been advocated .HQQHG\DQG2¶+DJDQwhich involves adjusting the model outputs 
using an error term to account for the difference between the model outputs and reality, however, it is 
unlikely that the required data will be available to the modeller. Research is currently ongoing (Strong et 
al., 2009) to evaluate the feasibility of this method. Both the model averaging approach and the 
discrepancy approach require further research before they can be used routinely in health care decision 
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models. In parallel, it is essential that methodologies for developing the initial model structure are 
appropriate and transparent. However, current approaches for structural development are not well defined, 
and as a result this process is inconsistent between modellers (Chilcott et al., 2009). Further research is 
therefore also required in this area. 
 
 
Comparison of our taxonomy of uncertainty with that of Morgan and Henrion 
 
Compared with previous taxonomies of uncertainty the one we have defined as relevant for health 
technology assessments is small [PT ± 127 685( ³60$//´ ,6 $335235$7(. WOULD BE 
HAPPIER SAYING THAT WHILST THE TAXONOMIES DIFFER IN THEIR CATEGORISATIONS, 
THEY ACTUALLY CONSIDER VERY SIMILAR THINGS], primarily as only the key areas related to 
health technology assessment have been defined. For completeness we have compared our taxonomy with 
that of Morgan and Henrion (Morgan and Henrion 1990) which has a much wider breadth and which 
details seven sources of uncertainty: Statistical variation; subjective judgement; linguistic imprecision; 
variability; inherent randomness; disagreement; and approximation. 
 
6WDWLVWLFDOYDULDWLRQDQGDSSUR[LPDWLRQDUHLQFOXGHGZLWKLQRXUWD[RQRP\DVµSDUDPHWHUXQFHUWDLQW\¶DQG
µVWUXFWXUDOXQFHUWDLQW\¶ respectively. The need for subjective judgement is reduced as the trials required 
for pharmacotherapy licensing are conducted in the appropriate population. Where the results need to be 
translated to a different population (for age, ethnicity or disease severity reasons) the cost per QALY is 
typically considered by an appraisal committee with the aid of sensitivity analyses. Linguistic imprecision 
is generally not an issue due to the formation of a tightly defined scope, which explicitly lists the 
population, intervention, comparators and outcomes to be considered [PT ± BUT THE SCOPE DOESN¶7
D,&7$7( :+$7 7+( 02'(/ 6+28/' /22. /,.( '2(61¶7 7+,6 $/62 $33/< :,7+
RESPECT TO MODEL DEVELOPMENT DECISIONS?. Variability and inherent randomness are not 
considered in health technology assessments [PT ± STRONGLY DISAGREE - VARIABILITY 
CERTAINLY IS], whilst disagreement is typically not relevant as whilst there may be inherent 
uncertainty in the biological action of an intervention, the key outcome measures (such as death or 
number of fractures) will not be affected and are reported in the clinical trials [PT ± AGREE WITH 
HAZEL ± DISAGREEMENT IS BASICALLY STRUCTURAL UNCERTAINTY]. 
 
 
 
 
Representing uncertainty around the objective function 
 
Cost effectiveness acceptability curves (CEACs) (Fenwick et al., 2001) explore the likelihood of 
optimality for each intervention and are used to display the uncertainty in the cost effectiveness results. 
CEACs plot the proportion of Monte Carlo simulations in which an intervention is estimated to be most 
cost-effective using different cost per QALY thresholds. An illustrative CEAC is shown in Figure 1, 
which highlights that for a specified population, as the threshold increases the proportions of simulations 
where silver-donating antimicrobial bandages were estimated to be more cost-effective than standard 
dressings increased. (Michaels et al., 2009)  
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Figure 1: An illustrative CEAC 
 
 
Importantly, the CEAC does not indicate which treatment is most cost-effective; this must be determined 
by calculating expected incremental cost per QALY values and comparing with an appropriate threshold. 
The proportion of times that the intervention that is estimated to be most cost-effective at a given 
threshold was actually most cost-effective in the PSA is displayed on a cost effectiveness acceptability 
frontier (CEAF). (Fenwick et al., 2001) Within CEAFs only the most cost-effective treatment at each 
threshold is plotted against the proportion of parameter configurations in which that intervention was 
estimated to be most cost-effective. In the example provided in Figure 1, the CEAF would follow the 
µVWDQGDUG GUHVVLQJV¶ FXUYH XQWLO WKH expected incremental cost per QALY value associated with silver 
GRQDWLQJ GUHVVLQJV ZDV UHDFKHG DW ZKLFK SRLQW WKH &($) ZRXOG XVH WKH µVLOYHU GRQDWLQJ GUHVVLQJV¶
curve. 
 
Uncertainty surrounding the cost-effectiveness ratio is typically reported as the 95% range of the results 
produced by the PSA, with a percentile methodology used selecting the 2.5% and 97.5% values from the 
ranked cost per QALY values [PT ± STRONGLY DISAGREE. CONFIDENCE INTERVALS ARE NOT 
OFTEN REPORTED DUE TO PROBLEMS IN PRODUCING THESE FOR A RATIO]. It is not 
uncommon when there is large uncertainty in the relative efficacy of a treatment compared with a 
comparator for this 95% confidence interval to range from dominated (a higher cost and less QALYs than 
the comparator) to dominating (a lower cost and higher QALYs than the comparator). Far less often 
reported, but arguably of more value, is the uncertainty in the mean cost per QALY ratio, which could be 
used to determine if sufficient PSA iterations have been performed. One approach used to estimate this is 
jackknifing (Inglehardt, 1975), which is summarised in Law (Law, 2007), which provides an upper and 
lower estimate of the mean cost per QALY, and also reduces the statistical bias that comes from classical 
estimates of a non-linear function such as the cost per QALY ratio.  
 
Alternative decision making criteria 
 
The NICE Reference case suggests a number of scenarios in which the appraisal committee has discretion 
to use an alternative cost per QALY threshold than £20,000. These include: the degree of certainty around 
the cost per QALY, with the committee being more cautious about recommending a technology where 
there is large uncertainty; when there are strong reasons to believe that the change in utility associated 
with a treatment has been inadequately captured; and if the technology has an innovative nature, which 
has not been adequately captured in the QALY measure. Formal scoring and ranking methods such as 
multi-creiteria decision analyses are not used within health economics. 
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In addition, NICE guidelines suggest that a higher cost per QALY threshold may be applied for some 
interventions aimed at end of life care. To meet the µEnd of Life¶ criteria the following must be met: the 
treatment is indicated for patients with a short life expectancy, normally less than 24 months, there is 
sufficient evidence that the treatment provides a life extension of at least three months compared with 
current NHS treatment and that the treatment is licensed or otherwise indicated for small patient 
populations. (NICE 2009)  
 
Value of additional information 
 
Value of additional information techniques are becoming more widespread in health economic evaluation. 
These methods aim to quantify the value of undertaking further research in order to reduce, or even 
eliminate parameter uncertainty. As such, these methods can be used as a means of prioritising and 
planning future research to ensure that research funding is targeted at those areas in which reducing 
current uncertainty is expected to be of most value. The simplest form is that of Expected Value of 
Perfect Information (EVPI) (Claxton and Posnett, 1996), which is defined as the maximum investment a 
decision-maker would be willing to pay to eliminate all parameter uncertainty from the decision problem. 
EVPI is initially calculated in terms of a defined unit (typically per patient) and then multiplied by the 
number of people expected to benefit from eliminating all parameter uncertainty to form an estimate of 
total EVPI.  EVPI per person is relatively high where there is large uncertainty in the adoption decision; 
conversely where there is only a small probability of error and the impact of an incorrect decision is small 
the EVPI per person will be relatively low. EVPI can be directly calculated from the PSA. Global EVPI is 
calculated as the average of the individual EVPI values. 
 
An adaptation of EVPI evaluates the maximum value of removing all uncertainty in one, or a subset of 
parameters and has been defined as the expected value of partial perfect information (EVPPI); (Felli and 
Hazen, 1998). However, this is computationally more expensive to perform as it requires two nested 
Monte Carlo sampling levels (Brennan and Kharroubi, 2007). In the absence of methods to reduce such 
computational expense, such as meta-modelling or efficient sampling processes, the EVPPI process can 
be prohibitive (Tappenden et al, 2004). A more advanced method for determining the value of added 
information, the expected value of sample information (EVSI) has been proposed (Ades et al., 2004) 
which explicitly takes into account that some uncertainty will remain even with large sample sizes. The 
EVSI methodology simulates the results from the proposed research and synthesises the simulated data 
with prior knowledge to form a posterior distribution: the larger the trial size the more the posterior 
distribution resembles the simulated data. The posterior distribution is then used in PSA. The optimal trial 
size from the options evaluated can then be estimated based on the costs of conducting the trial and the 
expected net benefit of the sampled information. The application of EVSI is becoming more common. 
(Stevenson et al., 2009, Stevenson et al., 2011) [PT ± THERE IS A REVIEW OF THE USE OF VOI ± 
THINK IT WAS 2005 IN EITHER VIH OR PHARMACOECONOMICS]. The validity of the results 
estimated from these techniques is dependent upon the appropriate characterisation of uncertainty. 
 
Conclusion 
The above discussion has provided a synopsis of current approaches to handling uncertainty in health 
economic models. The emphasis of methods development has been placed on parameter uncertainty and a 
clear reference case has been developed, although uncertainty still exists. Less attention has been paid to 
methods for formally incorporating structural uncertainty. Until adequate methods are developed to 
explicitly include structural uncertainty, true decision uncertainty may be underestimated, which may 
have implications for decision making both in terms of whether an intervention should be publically 
funded and whether additional research should be undertaken. 
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